Home › Companies › Verona Pharma Plc › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Verona Pharma Plc’s Form 8-K, filed April 25, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of April 24, 2025: 10 items on Verona Pharma Plc’s Form 8-K, filed April 25, 2025: 10 passed (calculated).
Notable dissent: 1 say-on-pay vote (72.3% support); 1 other board item (27.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Verona Pharma Plc in the interactive database Compare manager voting policies
These tallies are Verona Pharma Plc’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 25, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. To re-elect Kenneth Cunningham, M.D. as a Director of the Company | 581,835,715 | 13,000,884 | -- | 59,466,152 | -- | 98% | Passed (calculated) | — |
| 2. To re-elect Vikas Sinha as a Director of the Company | 584,744,107 | 10,160,892 | -- | 59,397,752 | -- | 98% | Passed (calculated) | — |
| 3. To re-elect James Brady as a Director of the Company | 590,232,355 | 4,675,044 | -- | 59,395,352 | -- | 99.2% | Passed (calculated) | — |
| 4. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2024 and the report of the auditors thereon (the "2024 U.K. Annual Report") | 594,832,683 | 163,844 | -- | 59,306,224 | -- | 99.9% | Passed (calculated) | — |
| 5. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2024, as set out on pages 21 to 43 of the 2024 U.K. Annual Report | 431,170,660 | 163,665,531 | -- | 59,466,560 | -- | 72% | Passed (calculated) | — |
| 6. To re-appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders | 654,070,652 | 163,844 | -- | 59,306,224 | -- | 99.9% | Passed (calculated) | — |
| 7. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025 | 594,925,203 | 46,368 | -- | 59,331,180 | -- | 99.9% | Passed (calculated) | — |
| 8. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers | 429,961,621 | 164,822,463 | -- | 59,518,667 | -- | 72% | Passed (calculated) | — |
| 9. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to con | 587,144,235 | 7,553,188 | -- | 59,605,328 | -- | 99% | Passed (calculated) | — |
| 10. Subject to and conditional upon the passing of resolution 13 above, to authorize the Directors pursuant to Section 570 and 573 of the Companies Act to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authori | 586,337,508 | 8,566,411 | -- | 59,398,832 | -- | 99% | Passed (calculated) | — |
Source: Verona Pharma Plc, Form 8-K, filed with the SEC on April 25, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
197 asset managers disclosed a vote on at least one Verona Pharma Plc item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Verona Pharma Plc’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To re-elect Kenneth Cunningham as a director of the Company.
Verona Pharma Plc’s own tally for this item (“1. To re-elect Kenneth Cunningham, M.D. as a Director of the Company”): 581,835,715 for, 13,000,884 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 11,425,081 for, 1,086,145 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 534,153 | 0 | 0 | Against |
| Fidelity | 279,290 | 204,992 | 0 | 0 | Mixed |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 0 | 289,282 | 0 | 0 | Against |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 4,795 | 57,718 | 0 | 0 | Mixed |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).
98% Majority: yes · of votes cast
Description as filed by funds: To re-elect Vikas Sinha as a director of the Company.
Verona Pharma Plc’s own tally for this item (“2. To re-elect Vikas Sinha as a Director of the Company”): 584,744,107 for, 10,160,892 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 12,267,481 for, 243,745 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| Fidelity | 279,290 | 204,992 | 0 | 0 | Mixed |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 62,513 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).
99.2% Majority: yes · of votes cast
Description as filed by funds: To re-elect James Brady as a director of the Company.
Verona Pharma Plc’s own tally for this item (“3. To re-elect James Brady as a Director of the Company”): 590,232,355 for, 4,675,044 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 12,306,234 for, 204,992 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| Fidelity | 279,290 | 204,992 | 0 | 0 | Mixed |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 62,513 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
Description as filed by funds: To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Companies Act does not apply to any such allotment. (Special Resolution)
The 50 asset managers below reported 12,511,219 for, 7 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| Fidelity | 484,282 | 0 | 0 | 0 | For |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 62,513 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).
99% Majority: yes · of votes cast
Description as filed by funds: To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of pounds7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company's existing ordinary share capital as at the close of business on March 11, 2025 (being the latest practicable date prior to publication of this document)).
Verona Pharma Plc’s own tally for this item (“9. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company or”): 587,144,235 for, 7,553,188 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 6,052,436 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Fidelity | 450,559 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Prudential/PGIM | 73,500 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 38,753 | 0 | 0 | 0 | For |
| Vanguard | 31,922 | 0 | 0 | 0 | For |
| Equitable | 19,284 | 0 | 0 | 0 | For |
| STEWARD FUNDS, INC. | 15,952 | 0 | 0 | 0 | For |
| PENN SERIES FUNDS INC | 7,489 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,756 | 0 | 0 | 0 | For |
| ProShares | 3,200 | 0 | 0 | 0 | For |
| First Trust | 350 | 0 | 0 | 0 | For |
| Aberdeen | 7 | 0 | 0 | 0 | For |
99% Majority: yes · of votes cast
Description as filed by funds: To Authorize The Board Of Directors To Exercise All The Powers Of The Company To Allot Shares In The Company Or Grant Rights To Subscribe For Or To Convert Any Security Into Shares In The Company Up To An Aggregate Nominal Amount Of PS7,031,895 (Being Up To A Maximum Of 140,637,892 Shares Representing 20% Of The Company's Existing Ordinary Share Capital As At The Close Of Business On March 11, 2025 (Being The Latest Practicable Date Prior To Publication Of This Document)).
Verona Pharma Plc’s own tally for this item (“9. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company or”): 587,144,235 for, 7,553,188 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 18 asset managers below reported 2,437,682 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| Prudential/PGIM | 396,548 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| Vanguard | 80,979 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| MassMutual | 39,899 | 0 | 0 | 0 | For |
| Fidelity | 33,723 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 33,064 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 25,737 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 16,315 | 0 | 0 | 0 | For |
| New York Life | 13,858 | 0 | 0 | 0 | For |
| Nationwide | 7,479 | 0 | 0 | 0 | For |
| Brighthouse | 4,795 | 0 | 0 | 0 | For |
| Forethought Variable Insurance Trust | 2,278 | 0 | 0 | 0 | For |
| Victory Capital | 1,321 | 0 | 0 | 0 | For |
| Principal | 425 | 0 | 0 | 0 | For |
99% Majority: yes · of votes cast
Description as filed by funds: To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company's existing ordinary share capital as at the close of business on March 11, 2025 (being the latest practicable date prior to publication of this document)).
Verona Pharma Plc’s own tally for this item (“9. To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the "Companies Act") to exercise all the powers of the Company to allot shares in the Company or”): 587,144,235 for, 7,553,188 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 15 asset managers below reported 4,021,108 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| Brighthouse | 57,718 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| AMG FUNDS | 34,300 | 0 | 0 | 0 | For |
| AdvisorShares Trust | 23,160 | 0 | 0 | 0 | For |
| AMG Funds IV | 8,479 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 3,969 | 0 | 0 | 0 | For |
| Advisors Preferred Trust | 1,752 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 1,183 | 0 | 0 | 0 | For |
| Strategy Shares | 455 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 103 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To Receive And Adopt The U.K. Statutory Annual Accounts And Directors Report For The Year Ended 31 December 2024.
Verona Pharma Plc’s own tally for this item (“4. To receive and adopt the U.K. statutory annual accounts and Directors' report for the year ended December 31, 2024 and the report of the auditors thereon (the "2024 U.K. Annual Report")”): 594,832,683 for, 163,844 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 50 asset managers below reported 12,511,226 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| Fidelity | 484,282 | 0 | 0 | 0 | For |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 62,513 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 50 asset managers. All 50 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Prior year: 96.2% for (April 26, 2024 meeting) ▼ 23.9 pts
Description as filed by funds: To approve, on an advisory (non- binding) basis, the compensation of the Company's named executive officers.
Verona Pharma Plc’s own tally for this item (“8. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers”): 429,961,621 for, 164,822,463 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,877,801 | 5,564 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,479,841 | 0 | 0 | Against |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 0 | 910,935 | 0 | 0 | Against |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 534,153 | 0 | 0 | Against |
| Fidelity | 0 | 484,282 | 0 | 0 | Against |
| Prudential/PGIM | 73,500 | 396,548 | 0 | 0 | Mixed |
| Allspring | 0 | 431,886 | 0 | 0 | Against |
| Hartford | 0 | 352,933 | 0 | 0 | Against |
| BlackRock | 0 | 289,282 | 0 | 0 | Against |
| American Century | 0 | 244,311 | 0 | 0 | Against |
| Legg Mason | 0 | 184,500 | 0 | 0 | Against |
| Vanguard | 31,922 | 80,979 | 0 | 0 | Mixed |
| John Hancock | 0 | 78,922 | 0 | 0 | Against |
| Northwestern Mutual | 0 | 67,071 | 0 | 0 | Against |
| Brighthouse | 0 | 62,513 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 61,912 | 0 | 0 | Against |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 60,301 | 0 | 0 | Against |
| Russell Investments | 0 | 47,785 | 0 | 0 | Against |
| Neuberger Berman | 0 | 45,711 | 0 | 0 | Against |
| Guardian Variable Products Trust | 0 | 43,879 | 0 | 0 | Against |
| Artisan | 0 | 42,453 | 0 | 0 | Against |
Fund voting reports, all 51 managers: 6,389,402 for, 6,147,244 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 4,897,113 | 0 | 0 | 0 | For |
| Janus Henderson | 3,735,089 | 36,848 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 3,457,850 | 0 | 0 | 0 | For |
| RTW INVESTMENTS, LP | 2,755,802 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 2,688,566 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 1,890,827 | 0 | 0 | Against |
| T. Rowe Price | 0 | 1,812,021 | 0 | 0 | Against |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 0 | 1,742,614 | 0 | 0 | Against |
| MAVERICK CAPITAL LTD | 1,648,290 | 0 | 0 | 0 | For |
| Wellington | 0 | 1,575,013 | 0 | 0 | Against |
| Vivo Capital, LLC | 1,438,806 | 0 | 0 | 0 | For |
| Point72 | 0 | 1,420,324 | 0 | 0 | Against |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 0 | 1,105,918 | 0 | 0 | Against |
| Duquesne Family Office LLC | 1,002,080 | 0 | 0 | 0 | For |
| Putnam | 0 | 976,789 | 0 | 0 | Against |
| LORD, ABBETT & CO. LLC | 892,028 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 862,886 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 760,907 | 0 | 0 | 0 | For |
| SEB Investment Management AB | 0 | 754,564 | 0 | 0 | Against |
| Woodline Partners LP | 659,949 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 615,352 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 4,157 | 606,208 | 0 | 0 | Against |
| Hood River Capital Management LLC | 609,311 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 512,780 | 0 | 0 | 0 | For |
Institutional-manager reports, all 160 managers: 29,274,244 for, 18,004,461 against, 4,782 not voted, 7,648 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Description as filed by funds: To Receive And Approve, As A Non-Binding Advisory Resolution, The U.K. Statutory Directors Remuneration Report For The Year Ended 31 December 2024.
Verona Pharma Plc’s own tally for this item (“5. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors' Remuneration Report for the year ended December 31, 2024, as set out on pages 21 to 43 of the 2024 U.K. Annual Report”): 431,170,660 for, 163,665,531 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,877,801 | 5,564 | 0 | 0 | For |
| T. Rowe Price | 0 | 1,479,841 | 0 | 0 | Against |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 0 | 910,935 | 0 | 0 | Against |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 534,153 | 0 | 0 | Against |
| Fidelity | 0 | 484,282 | 0 | 0 | Against |
| Prudential/PGIM | 73,500 | 396,548 | 0 | 0 | Mixed |
| Allspring | 0 | 431,886 | 0 | 0 | Against |
| Hartford | 0 | 352,933 | 0 | 0 | Against |
| BlackRock | 0 | 289,282 | 0 | 0 | Against |
| American Century | 0 | 244,311 | 0 | 0 | Against |
| Legg Mason | 0 | 184,500 | 0 | 0 | Against |
| Vanguard | 31,922 | 80,979 | 0 | 0 | Mixed |
| John Hancock | 0 | 78,922 | 0 | 0 | Against |
| Northwestern Mutual | 0 | 67,071 | 0 | 0 | Against |
| Brighthouse | 0 | 62,513 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 61,912 | 0 | 0 | Against |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 60,301 | 0 | 0 | Against |
| Russell Investments | 0 | 47,785 | 0 | 0 | Against |
| Neuberger Berman | 0 | 45,711 | 0 | 0 | Against |
| Guardian Variable Products Trust | 0 | 43,879 | 0 | 0 | Against |
| Artisan | 0 | 42,453 | 0 | 0 | Against |
Fund voting reports, all 51 managers: 6,389,402 for, 6,147,244 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Hood River Capital Management LLC | 609,311 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 512,780 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 0 | 194,149 | 0 | 0 | Against |
| Desjardins Global Asset Management Inc. | 0 | 83,589 | 0 | 0 | Against |
| Treasurer of the State of North Carolina | 0 | 33,178 | 0 | 0 | Against |
| BlackRock | 0 | 12,921 | 0 | 0 | Against |
| Argent Trust Co | 8,150 | 0 | 0 | 0 | For |
| Liberty Mutual Group Asset Management Inc. | 0 | 3,823 | 0 | 0 | Against |
| WRAPMANAGER INC | 0 | 3,658 | 0 | 0 | Against |
| Vident Advisory, LLC | 287 | 0 | 0 | 0 | For |
| SouthState Corp | 223 | 0 | 0 | 0 | For |
| NAPLES GLOBAL ADVISORS, LLC | 100 | 0 | 0 | 0 | For |
Institutional-manager reports, all 12 managers: 1,130,851 for, 331,318 against.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
Verona Pharma Plc’s own tally for this item (“6. To re-appoint Ernst & Young LLP as the Company's auditors, to hold office until the conclusion of the next annual general meeting of shareholders”): 654,070,652 for, 163,844 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 12,536,646 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| Fidelity | 484,282 | 0 | 0 | 0 | For |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 62,513 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025.
Verona Pharma Plc’s own tally for this item (“7. To authorize the Audit and Risk Committee to determine the auditors' remuneration for the year ending December 31, 2025”): 594,925,203 for, 46,368 against, per its Form 8-K filed April 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 12,536,646 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MUTUAL FUND SERIES TRUST | 2,883,365 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,479,841 | 0 | 0 | 0 | For |
| Federated Hermes | 1,267,761 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,163,880 | 0 | 0 | 0 | For |
| Putnam | 910,935 | 0 | 0 | 0 | For |
| Lord Abbett | 825,645 | 0 | 0 | 0 | For |
| Loomis Sayles | 534,153 | 0 | 0 | 0 | For |
| Fidelity | 484,282 | 0 | 0 | 0 | For |
| Prudential/PGIM | 470,048 | 0 | 0 | 0 | For |
| Allspring | 431,886 | 0 | 0 | 0 | For |
| Hartford | 352,933 | 0 | 0 | 0 | For |
| BlackRock | 289,282 | 0 | 0 | 0 | For |
| American Century | 244,311 | 0 | 0 | 0 | For |
| Legg Mason | 184,500 | 0 | 0 | 0 | For |
| Vanguard | 112,901 | 0 | 0 | 0 | For |
| John Hancock | 78,922 | 0 | 0 | 0 | For |
| Northwestern Mutual | 67,071 | 0 | 0 | 0 | For |
| Brighthouse | 62,513 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 61,912 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 60,388 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 60,301 | 0 | 0 | 0 | For |
| Russell Investments | 47,785 | 0 | 0 | 0 | For |
| Neuberger Berman | 45,711 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 43,879 | 0 | 0 | 0 | For |
| Artisan | 42,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 687,930,486 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | MUTUAL FUND SERIES TRUST | 0.42% |
| 2 | T. Rowe Price | 0.22% |
| 3 | Federated Hermes | 0.18% |
| 4 | JANUS INVESTMENT FUND | 0.17% |
| 5 | Putnam | 0.13% |
| 6 | Lord Abbett | 0.12% |
| 7 | Loomis Sayles | 0.08% |
| 8 | Fidelity | 0.07% |
| 9 | Prudential/PGIM | 0.07% |
| 10 | Allspring | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 0.71% |
| 2 | Janus Henderson | 0.55% |
| 3 | Frazier Life Sciences Management, L.P. | 0.50% |
| 4 | RTW INVESTMENTS, LP | 0.40% |
| 5 | NEA Management Company, LLC | 0.39% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.27% |
| 7 | T. Rowe Price | 0.26% |
| 8 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 0.25% |
| 9 | MAVERICK CAPITAL LTD | 0.24% |
| 10 | Wellington | 0.23% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| RA Capital Management affiliates | 62,223,536 | 9.05% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Perceptive Advisors LLC | 52,527,464 | 7.64% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Growth Equity Opportunities 17, LLC | 32,678,025 | 4.75% | Schedule 13D, filed January 21, 2025 |
| Maverick Capital, Ltd. | 25,028,128 | 3.64% | Schedule 13G, filed February 14, 2025 |
| David Zaccardelli, Pharm.D. | 11,513,024 | 1.67% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Mark W. Hahn | 10,601,848 | 1.54% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Kathleen Rickard, M.D. | 2,625,752 | 0.38% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| T. Rowe Price | 1,866,280 | 0.27% | Form 13F, quarter ended March 31, 2025 |
| Claire Poll | 1,718,728 | 0.25% | Proxy statement (DEF 14A), table as of March 1, 2025 |
| Morgan Stanley | 1,624,127 | 0.24% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 687,930,486 shares outstanding, as reported by Verona Pharma Plc on its Form 10-Q dated June 30, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Verona Pharma Plc's shareholder meeting held April 24, 2025, in the 2024-2025 proxy season, 197 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,245 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of the Company's named… — FOR was 72% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Verona Pharma Plc's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 25, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Verona Pharma Plc’s 10-Q dated June 30, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Verona Pharma Plc proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Verona Pharma Plc 2025 Annual Meeting: Vote Results & How Funds Voted”, https://proxyvotesnow.com/company/verona-pharma-plc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.